Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis

Kristian Reich; Xenophon Baraliakos; Laura C. Coates; Boni Elewski; Weibin Bao; Torben Kasparek; Corine Gaillez; Effie Pournara; Maher Aassi; Chiara Perella; Alice B. Gottlieb

doi:10.1111/bjd.21233

Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis

Kristian Reich, Xenophon Baraliakos, Laura C. Coates, Boni Elewski, Weibin Bao, Torben Kasparek, Corine Gaillez, Effie Pournara, Maher Aassi, Chiara Perella, Alice B. Gottlieb

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English
Pages (from-to)	438-441
Number of pages	4
Journal	British Journal of Dermatology
Volume	187
Issue number	3
DOIs	https://doi.org/10.1111/bjd.21233
State	Published - Sep 2022

Access to Document

10.1111/bjd.21233

Cite this

Reich, K., Baraliakos, X., Coates, L. C., Elewski, B., Bao, W., Kasparek, T., Gaillez, C., Pournara, E., Aassi, M., Perella, C., & Gottlieb, A. B. (2022). Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis. British Journal of Dermatology, 187(3), 438-441. https://doi.org/10.1111/bjd.21233

@article{1b37140b27b94cc88c04df02a7fbd1c3,

title = "Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis",

author = "Kristian Reich and Xenophon Baraliakos and Coates, {Laura C.} and Boni Elewski and Weibin Bao and Torben Kasparek and Corine Gaillez and Effie Pournara and Maher Aassi and Chiara Perella and Gottlieb, {Alice B.}",

note = "Funding Information: Conflicts of interest: K.R. is CSO at MoonLake Immunotherapeutics AG and has participated in clinical trials sponsored by AbbVie, Amgen, Biogen Idec, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen‐Cilag, LEO, Lilly, Medac, MSD, Novartis, Pfizer, Takeda and Vertex; and has served as a consultant for AbbVie, Amgen, Biogen Idec, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen‐Cilag, LEO, Lilly, Medac, MSD, Novartis, Pfizer, Takeda and Vertex. X.B. has received grant/research support from AbbVie and Novartis; served as a consultant for AbbVie, BMS, Celgene, Chugai, Galapagos, Gilead, MSD, Novartis, Pfizer and UCB; and participated in a speakers bureau for AbbVie, BMS, Celgene, Chugai, MSD, Novartis, Pfizer and UCB. L.C.C. has received grant/research support from AbbVie, Janssen, Lilly, Novartis and Pfizer and served as a consultant for AbbVie, Amgen, Biogen, Celgene, Pfizer, UCB, Boehringer Ingelheim, Novartis, Lilly, Janssen, Sun Pharma, Prothena and Gilead. B.E. received research grants from AbbVie, Anaptys‐Bio, Boehringer Ingelheim, Celgene, Incyte, Leo, Lilly, Merck, Menlo, Novartis, Pfizer, Regeneron, Sun, Valeant and Vanda for investigator services, and honoraria from Boehringer Ingelheim, BMS, Celgene, Leo, Lilly, Menlo, Novartis, Pfizer, Sun, Valeant and Verrica for consultant services. A.B.G. has received research grants, consultation fees, stock options (Xbiotech) or speaker honoraria for lectures from Janssen Inc.; Celgene Corp., Beiersdorf, Bristol Myers Squibb Co., UCB, Novartis, Incyte, Lilly, Sun Pharmaceutical Industries, Leo, Avotres Therapeutics, Boehringer Ingelheim, Janssen, Incyte, Novartis and Xbiotech. W.B., M.A., T.K., E.P, C.P. and C.G. are employees of Novartis. Funding Information: All authors participated in the development of this research letter. The authors thank Esha Chakraborty and Sarabjeet Kaur Singh (Novartis Healthcare Pvt. Ltd., India) for editorial and medical writing support, which was funded by Novartis Pharma AG, Basel, Switzerland, in accordance with the Good Publication Practice (GPP3) guidelines ( http://www.ismpp.org/gpp3 ). ",

year = "2022",

month = sep,

doi = "10.1111/bjd.21233",

language = "English",

volume = "187",

pages = "438--441",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "3",

}

Reich, K, Baraliakos, X, Coates, LC, Elewski, B, Bao, W, Kasparek, T, Gaillez, C, Pournara, E, Aassi, M, Perella, C & Gottlieb, AB 2022, 'Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis', British Journal of Dermatology, vol. 187, no. 3, pp. 438-441. https://doi.org/10.1111/bjd.21233

TY - JOUR

T1 - Secukinumab demonstrates high and sustained efficacy in nail psoriasis

T2 - post hoc analysis from phase III trials in patients with psoriatic arthritis

AU - Reich, Kristian

AU - Baraliakos, Xenophon

AU - Coates, Laura C.

AU - Elewski, Boni

AU - Bao, Weibin

AU - Kasparek, Torben

AU - Gaillez, Corine

AU - Pournara, Effie

AU - Aassi, Maher

AU - Perella, Chiara

AU - Gottlieb, Alice B.

N1 - Funding Information: Conflicts of interest: K.R. is CSO at MoonLake Immunotherapeutics AG and has participated in clinical trials sponsored by AbbVie, Amgen, Biogen Idec, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen‐Cilag, LEO, Lilly, Medac, MSD, Novartis, Pfizer, Takeda and Vertex; and has served as a consultant for AbbVie, Amgen, Biogen Idec, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen‐Cilag, LEO, Lilly, Medac, MSD, Novartis, Pfizer, Takeda and Vertex. X.B. has received grant/research support from AbbVie and Novartis; served as a consultant for AbbVie, BMS, Celgene, Chugai, Galapagos, Gilead, MSD, Novartis, Pfizer and UCB; and participated in a speakers bureau for AbbVie, BMS, Celgene, Chugai, MSD, Novartis, Pfizer and UCB. L.C.C. has received grant/research support from AbbVie, Janssen, Lilly, Novartis and Pfizer and served as a consultant for AbbVie, Amgen, Biogen, Celgene, Pfizer, UCB, Boehringer Ingelheim, Novartis, Lilly, Janssen, Sun Pharma, Prothena and Gilead. B.E. received research grants from AbbVie, Anaptys‐Bio, Boehringer Ingelheim, Celgene, Incyte, Leo, Lilly, Merck, Menlo, Novartis, Pfizer, Regeneron, Sun, Valeant and Vanda for investigator services, and honoraria from Boehringer Ingelheim, BMS, Celgene, Leo, Lilly, Menlo, Novartis, Pfizer, Sun, Valeant and Verrica for consultant services. A.B.G. has received research grants, consultation fees, stock options (Xbiotech) or speaker honoraria for lectures from Janssen Inc.; Celgene Corp., Beiersdorf, Bristol Myers Squibb Co., UCB, Novartis, Incyte, Lilly, Sun Pharmaceutical Industries, Leo, Avotres Therapeutics, Boehringer Ingelheim, Janssen, Incyte, Novartis and Xbiotech. W.B., M.A., T.K., E.P, C.P. and C.G. are employees of Novartis. Funding Information: All authors participated in the development of this research letter. The authors thank Esha Chakraborty and Sarabjeet Kaur Singh (Novartis Healthcare Pvt. Ltd., India) for editorial and medical writing support, which was funded by Novartis Pharma AG, Basel, Switzerland, in accordance with the Good Publication Practice (GPP3) guidelines ( http://www.ismpp.org/gpp3 ).

PY - 2022/9

Y1 - 2022/9

UR - http://www.scopus.com/inward/record.url?scp=85131296874&partnerID=8YFLogxK

U2 - 10.1111/bjd.21233

DO - 10.1111/bjd.21233

M3 - Letter

C2 - 35257363

AN - SCOPUS:85131296874

SN - 0007-0963

VL - 187

SP - 438

EP - 441

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 3

ER -